In an report showing up in Character Biomedical Engineering, a group of experts from the UCLA David Geffen University of Medicine and UCLA University of Engineering report authentic-environment results on SwabSeq, a superior-throughput testing platform that works by using sequencing to take a look at thousands of samples at a time to detect COVID-19. They ended up able to carry out more than 80,000 checks in much less than two months, with the take a look at showing very superior sensitivity and specificity.
SwabSeq works by using sample-specific molecular barcodes to concurrently assess thousands of samples for the existence or absence of SARS-CoV-two, the virus that causes COVID-19. SwabSeq was granted Fda Unexpected emergency Use Authorization in October and is currently deployed at UCLA in a superior-complexity CLIA laboratory, which has executed in excess of a hundred and fifty,000 checks due to the fact December 2020. SwabSeq is a flexible protocol and can speedily scale up testing for novel pathogens, including COVID-19 and foreseeable future rising viruses.
“We have optimized SwabSeq to prioritize scale and very low price, critical elements that are lacking from latest COVID-19 diagnostics,” the authors create.
“These results demonstrate the probable of SwabSeq to be applied for SARS-CoV-two testing on an unprecedented scale,” reported Dr. Valerie Arboleda, Assistant Professor and lead scientist on the undertaking. “SwabSeq delivers a probable alternative to the require for population-vast testing to stem the pandemic.” In the months due to the fact, the group has ongoing to use the take a look at, and as of this date has executed more than a hundred and fifty,000 checks.
The groundbreaking technological innovation was formulated in a collaboration amongst experts at the Division of Computational Medicine affiliated with both of those the David Geffen University of Medicine and the Samueli University of Engineering at UCLA, the Division of Human Genetics, the Division of Pathology and Laboratory Medicine, and Octant, a start-up business founded and incubated at UCLA. SwabSeq is a modification of Octant’s technological innovation that is currently being used towards drug discovery and has been produced obtainable broadly to struggle the pandemic. UCLA experts have been main a broader coalition of tutorial and industrial labs all around the place and the environment to create the technological innovation to scale up COVID-19 testing.
Supplies delivered by University of California – Los Angeles Wellbeing Sciences. Note: Information might be edited for type and size.